Tuna BSDM news - SALT LAKE CITY, Oct 27, 2003 /PRNewswire-FirstCall via COMTEX/ --BSD Medical Corp.(OTC Bulletin Board: BSDM) has introduced a family of newly FDA approvedoperating systems for treating such cancers as breast, prostate, head andneck, brain and melanoma, at the largest radiation oncology conference held inAmerica. This product introduction was especially timely and opportunebecause Salt Lake City, the location of BSD headquarters, was also host cityof the 2003 American Society for Therapeutic Radiology and Oncology (ASTRO)conference, just concluded. BSD received FDA approval for the new operatingsystems only days before the national conference. Ten thousand physicians,physicists and other medical personnel engaged in cancer therapy attended thefive-day ASTRO meetings. BSD presented its products in three separate boothdisplays.
The new BSD systems revolutionize the treatment of cancer patients usingsuperficial and interstitial hyperthermia therapy. This approval opens thedoor to the commercial introduction of four new systems to sales in the UnitedStates. In addition to treating melanoma, recurring breast cancer and othercancers requiring superficial therapy, these new products are intended to becompanion systems to the more than 1,500 installed brachytherapy systems usedfor interstitial radiotherapy.
The new systems were six years in planning and development, precipitatedby a 1996 publication of a Johns Hopkins Hospital study in CANCER (theofficial journal of the American Cancer Society), which concluded thatinterstitial hyperthermia was convenient, safe and effective in treating humancancers (see CANCER, June 1, 1996, pp. 2363-2370). Numerous other studieshave supported this conclusion.
The new products are compact, portable and ergonomically engineered foruse in a demanding hospital environment. A high-resolution graphic touch-screen display drives the new systems, upstaging anything ever before seen inoperator control for similar applications. The over 50,000 lines of code inthe new systems software are supported by new high-performance hardware, whichthe FDA also approved as part of the configuration of the new operatingsystem.
Superficial hyperthermia is used to non-invasively treat cancerous tumorslocated within a few centimeters of the surface of the body, such as melanomaand recurrent breast cancer. Interstitial hyperthermia is used in treatingprostate cancer, breast cancer, head and neck cancer and a variety of othercancers. For further information about BSD Medical and these new products, orto find further information about hyperthermic oncology or treatment centers,visit the BSD web site at ( www.bsdmc.com ).
Statements contained in this press release that are not historical factsare forward looking statements, as that item is defined in the PrivateSecurities Litigation Reform Act of 1995. Such forward-looking statements aresubject to risks and uncertainties (detailed in the Company's filings with theSecurities and Exchange Commission) that could cause actual results to differmaterially from estimated results.
SOURCE BSD Medical Corp. |
